HIV treatment showdown: could simpler drug regimens reduce inflammation?

NCT ID NCT05699785

Ongoing Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at HIV patients over 40 (or those on HIV therapy for over 10 years) who switched to either a three-drug or a two-drug antiretroviral regimen. Researchers will measure markers of inflammation in the blood and track how many patients develop other health conditions over three years. The goal is to see if a simpler, two-drug therapy leads to less inflammation and fewer comorbidities than the standard three-drug approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine)
What this could lead to: If successful, this could help doctors choose the best HIV treatment regimen to reduce long-term inflammation and lower the risk of other health problems.
What could go wrong: This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all HIV patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

CH Simone VEIL

Cannes, 06614, France
CHU Nice

Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.